KING OF PRUSSIA, PA, April 28 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, has formed a
strategic collaboration with Compendia Bioscience, Inc. to deliver a novel
solution, OncoPredictor(SM), to improve the development of drugs to treat
OncoPredictor combines MDS Pharma Services' OncoPanel(TM) with Compendia
Bioscience's Oncomine(TM) for a solution that will help identify cancer
patient populations most likely to respond to a new or existing cancer
therapy. As a result, research is more efficient and therapies can be targeted
to those most likely to benefit.
"MDS Pharma Services is pleased to collaborate with Compendia Bioscience
to develop OncoPredictor(SM), a solution that will help clients developing
cancer treatments to do so more quickly and effectively," said MDS Pharma
Services President David Spaight. "Our pharmaceutical and biotechnology
clients seek to determine the efficacy of their compounds across cancer
genotypes and patient phenotypes. OncoPredictor(SM) will help provide the
answer with technology for information-based lead selection, predictive in
vivo study design and biomarker development."
OncoPanel(TM) offers high content screening of up to 240 cancer cell
lines for sensitivity to specific cancer drugs and drug combinations.
Compendia's Oncomine, a database of cancer genomic profiles coupled with a
Web-enabled analysis application, provides genomic characterization and
comparison of cancer cell lines to 2,000 disease signatures from more than
27,000 reference patients based on molecular, pathological and histological
sub-types. The OncoPredictor(SM) system will analyze drug sensitivity and
resistance of novel drugs and drug combinations to identify associations with
both disease sub-types and underlying tumor biology.
"Based on our experience working with the top companies pursuing
development of cancer treatments, we believe this integrated solution could
revolutionize cancer genomics for drug development," said Compendia CEO and
Co-founder Dan Rhodes, Ph.D. "MDS Pharma Services clearly provides unique
experience and capabilities, and we do not believe we could have identified a
better partner to co-develop this solution."
MDS Pharma Services is the only contract research organization with
firsthand experience of delivering high-quality cellular data on such a large
scale using the exact growth and culture conditions from which the genomic
data in Oncomine(TM) was generated. Clients rely on MDS Pharma Services for
this large-scale screening because of its proven experience in developing
reliable cell line culture and growth conditions, providing consistent data
for the integration of genomic and functional information.
"Compendia Bioscience is a leader in the field of cancer genomics," Mr.
Spaight added. "Its Oncomine(TM) is a standard platform in the industry, and
we believe our joint solution - OncoPredictor(SM) - can also become a
cost-affordable industry standard in oncology drug development for both large
and small companies."
MDS Pharma Services Pharmacology/DMPK division offers biochemical,
cellular/functional, ADME/DMPK and in vivo assays for use in identifying lead
compounds, profiling for selectivity, determining the potential for adverse
events, evaluating efficacy and establishing proof of concept. To help speed
lead optimization earlier in the discovery phase and streamline the surest
path to clinic, the team offers extensive capabilities in molecular and
cellular pharmacology, including more than 800 assays, multiple assay
methodologies, high throughput screening with robotic automation, and expert
assay development. To view the extensive catalog of discovery assays, visit
the MDS Pharma Services' Pharmacology/DMPK Website at
About Compendia Bioscience's Oncomine(TM)
Oncomine(TM) combines a rapidly growing compendium of more than 30,000
expertly curated cancer genomic profiles with a sophisticated analysis engine
and a powerful Web application for data mining and visualization. Oncomine(TM)
facilitates target discovery and validation and supports the prioritization of
tumor populations for drug development. To learn more, go to
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to harnessing the global collection of
high throughput molecular data to provide researchers with the data and
analysis tools necessary to validate biomarker and gene target discoveries,
better understand mechanisms of disease, and optimize clinical outcomes. For
more information, go to www.compendiabio.com.
About MDS Pharma Services' OncoPanel(TM)
MDS Pharma Services' Oncopanel(TM) offers high-throughput cellular drug
profiling, relying on deep experience in cell culture and high content imaging
to systematically screen compounds across hundreds of cancer cell lines
About MDS Pharma Services
MDS Pharma Services, a business unit of MDS Inc., is committed to
delivering quality service on-time. We offer a full spectrum of resources to
meet the drug-discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically located
around the world, we apply advanced scientific and technological expertise
throughout the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research (bioequivalence,
phases I-IIa) and bioanalysis through to global clinical development (phases
IIb-IV), central lab and centralized cardiac services. For more information,
visit our Website at www.mdsps.com.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that
provides market-leading products and services that our customers need for the
development of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research, medical isotopes
for molecular imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,000 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information:
For further information: MEDIA: Mary C. Coyle, Communications Manager,
(610) 405-2325, email@example.com; INVESTORS: Kim Lee, (416) 213-4721,